• Developing First-in-class Axl Inhibitors for Multiple Aggressive Cancers

    Science
  • Pipeline of innovative AXL inhibitors

    Pipeline
  • Ongoing clinical trials in AML and non-small cell lung cancer

    Ongoing trials

The Science of BerGenBio

BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers. The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance – the cause of approximately 90 percent of cancer deaths. Inhibition of AXL kinase activity represents a novel approach to addressing a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering an opportunity to create important new therapeutic options for cancer patients.

Explore the science of BerGenBio